11,375 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Bought by XTX Topco Ltd

XTX Topco Ltd purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 11,375 shares of the company's stock, valued at approximately $630,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Jennison Associates LLC raised its holdings in Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock worth $138,432,000 after purchasing an additional 321,552 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Tarsus Pharmaceuticals by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company's stock worth $117,117,000 after purchasing an additional 17,839 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Tarsus Pharmaceuticals by 0.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company's stock worth $63,499,000 after purchasing an additional 5,565 shares in the last quarter. Invesco Ltd. boosted its position in shares of Tarsus Pharmaceuticals by 36.7% during the 4th quarter. Invesco Ltd. now owns 932,115 shares of the company's stock worth $51,611,000 after purchasing an additional 250,018 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Tarsus Pharmaceuticals by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 838,804 shares of the company's stock worth $46,456,000 after purchasing an additional 3,014 shares in the last quarter. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Trading Down 0.1 %

TARS traded down $0.04 on Thursday, hitting $49.96. 192,017 shares of the company were exchanged, compared to its average volume of 684,604. The firm has a fifty day simple moving average of $47.62 and a two-hundred day simple moving average of $48.02. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The stock has a market capitalization of $1.92 billion, a PE ratio of -13.07 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 3,084 shares of Tarsus Pharmaceuticals stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $154,539.24. Following the completion of the sale, the general counsel now owns 51,712 shares of the company's stock, valued at approximately $2,591,288.32. This trade represents a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bobak R. Azamian sold 8,534 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $427,638.74. Following the completion of the transaction, the chief executive officer now owns 53,635 shares in the company, valued at $2,687,649.85. This trade represents a 13.73 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,542 shares of company stock worth $1,581,173. 8.25% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Guggenheim reaffirmed a "buy" rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. HC Wainwright reissued a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Barclays reduced their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Jefferies Financial Group raised their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, Oppenheimer raised their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.